Cefazolin or nafcillin?: a commentary on the optimal treatment of methicillin-susceptible Staphylococcus aureus bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins

Paul O. Lewis; Kelly L. Covert; David Cluck

doi:10.21037/aoi.2018.10.01

Cefazolin or nafcillin? a commentary on the optimal treatment of methicillin-susceptible Staphylococcus aureus bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins

Paul O. Lewis
, Kelly L. Covert
, David Cluck

Department of Pharmacy Practice

Johnson City Medical Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Number of pages	5
Journal	Annals of Infection
Volume	2
Issue number	5
DOIs	https://doi.org/10.21037/aoi.2018.10.01
State	Published - Oct 22 2018

Access to Document

10.21037/aoi.2018.10.01License: CC BY-NC-ND

Cite this

@article{c0bafaa858fb48ae8761a31b837cd963,

title = "Cefazolin or nafcillin?: a commentary on the optimal treatment of methicillin-susceptible Staphylococcus aureus bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins",

author = "Lewis, \{Paul O.\} and Covert, \{Kelly L.\} and David Cluck",

year = "2018",

month = oct,

day = "22",

doi = "10.21037/aoi.2018.10.01",

language = "American English",

volume = "2",

journal = "Annals of Infection",

issn = "2616-2709",

number = "5",

}

TY - JOUR

T1 - Cefazolin or nafcillin?

T2 - a commentary on the optimal treatment of methicillin-susceptible Staphylococcus aureus bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins

AU - Lewis, Paul O.

AU - Covert, Kelly L.

AU - Cluck, David

PY - 2018/10/22

Y1 - 2018/10/22

U2 - 10.21037/aoi.2018.10.01

DO - 10.21037/aoi.2018.10.01

M3 - Article

SN - 2616-2709

VL - 2

JO - Annals of Infection

JF - Annals of Infection

IS - 5

ER -